Drug Patents owned by Bioxcel
1. List of Igalmi drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10792246 | BIOXCEL | Film formulations containing dexmedetomidine and methods of producing them |
Jun, 2039
(16 years from now) | |
| US11497711 | BIOXCEL | NA |
Jun, 2039
(16 years from now) | |
| US11478422 | BIOXCEL | Film formulations containing dexmedetomidine and methods of producing them |
Jun, 2039
(16 years from now) | |
| US11517524 | BIOXCEL | NA |
Jun, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Apr 5, 2025 |
Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 April, 2022
Treatment: Acute treatment of agitation associated with schizophrenia or bipolar i or ii disorder by sublingual administration
Dosage: FILM;BUCCAL, SUBLINGUAL
More Information on Dosage
IGALMI family patents
17
United States
6
China
3
European Union
2
Japan
1
Taiwan, Province of China
1
Korea, Republic of
1
Israel
1
Singapore
1
Australia
1
EA
1
Canada
1
Brazil
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic